CN109477107A - 一种抑制EGFR基因表达的siRNA及其前体和应用 - Google Patents

一种抑制EGFR基因表达的siRNA及其前体和应用 Download PDF

Info

Publication number
CN109477107A
CN109477107A CN201780027945.4A CN201780027945A CN109477107A CN 109477107 A CN109477107 A CN 109477107A CN 201780027945 A CN201780027945 A CN 201780027945A CN 109477107 A CN109477107 A CN 109477107A
Authority
CN
China
Prior art keywords
seq
sirna
sequence
egfr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780027945.4A
Other languages
English (en)
Other versions
CN109477107B (zh
Inventor
张辰宇
陈熹
梁宏伟
U·乌尔-拉赫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Micromedmark Biotech Co Ltd
Original Assignee
Jiangsu Micromedmark Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Micromedmark Biotech Co Ltd filed Critical Jiangsu Micromedmark Biotech Co Ltd
Publication of CN109477107A publication Critical patent/CN109477107A/zh
Application granted granted Critical
Publication of CN109477107B publication Critical patent/CN109477107B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供了一种抑制EGFR基因表达的siRNA，及其前体序列和用途。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201780027945.4A 2016-05-05 2017-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用 Active CN109477107B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610296445.8A CN107345231A (zh) 2016-05-05 2016-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用
CN2016102964458 2016-05-05
PCT/CN2017/083312 WO2017190695A1 (zh) 2016-05-05 2017-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用

Publications (2)

Publication Number Publication Date
CN109477107A true CN109477107A (zh) 2019-03-15
CN109477107B CN109477107B (zh) 2024-10-11

Family

ID=60202785

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610296445.8A Pending CN107345231A (zh) 2016-05-05 2016-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用
CN201780027945.4A Active CN109477107B (zh) 2016-05-05 2017-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610296445.8A Pending CN107345231A (zh) 2016-05-05 2016-05-05 一种抑制EGFR基因表达的siRNA及其前体和应用

Country Status (3)

Country Link
US (1) US11304970B2 (zh)
CN (2) CN107345231A (zh)
WO (1) WO2017190695A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958839A (zh) * 2021-02-25 2022-08-30 上海市东方医院（同济大学附属东方医院） 抑制肌肉瘤细胞中FOXO1基因表达的siRNA序列及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109971756A (zh) * 2018-12-21 2019-07-05 江苏命码生物科技有限公司 抑制EGFR表达的siRNA及其前体和应用
EP4073102A4 (en) * 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
CN112980837B (zh) * 2019-12-13 2023-07-04 深圳艾码生物科技有限公司 一种抑制HTT基因表达的siRNA及其前体和应用
CN112980838A (zh) * 2019-12-13 2021-06-18 南京大学 一种靶向型针对PTP1B的siRNA及其前体和应用
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
CN101353656A (zh) * 2008-07-24 2009-01-28 中国科学院广州生物医药与健康研究院 抑制表皮生长因子受体基因表达的siRNA及其应用
CN101429513A (zh) * 2008-05-22 2009-05-13 中国科学院微生物研究所 Rna诱导的沉默复合体介导的剪切位点及其应用
US20090149403A1 (en) * 2006-05-26 2009-06-11 Protiva Biotherapeutics, Inc. siRNA silencing of genes expressed in cancer
CN101801418A (zh) * 2007-06-22 2010-08-11 因特拉迪格姆公司 包括人类EGFR-siRNA的组合物及使用方法
US20110206697A1 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101225403A (zh) * 2007-01-17 2008-07-23 复旦大学附属中山医院 靶向表皮生长因子受体的小干扰rna重组腺病毒及其用途
WO2016177343A1 (zh) * 2015-05-05 2016-11-10 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US20090149403A1 (en) * 2006-05-26 2009-06-11 Protiva Biotherapeutics, Inc. siRNA silencing of genes expressed in cancer
CN101801418A (zh) * 2007-06-22 2010-08-11 因特拉迪格姆公司 包括人类EGFR-siRNA的组合物及使用方法
CN101429513A (zh) * 2008-05-22 2009-05-13 中国科学院微生物研究所 Rna诱导的沉默复合体介导的剪切位点及其应用
CN101353656A (zh) * 2008-07-24 2009-01-28 中国科学院广州生物医药与健康研究院 抑制表皮生长因子受体基因表达的siRNA及其应用
US20110206697A1 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958839A (zh) * 2021-02-25 2022-08-30 上海市东方医院（同济大学附属东方医院） 抑制肌肉瘤细胞中FOXO1基因表达的siRNA序列及应用

Also Published As

Publication number Publication date
CN107345231A (zh) 2017-11-14
US11304970B2 (en) 2022-04-19
US20190255090A1 (en) 2019-08-22
WO2017190695A1 (zh) 2017-11-09
CN109477107B (zh) 2024-10-11

Similar Documents

Publication Publication Date Title
CN109477107A (zh) 一种抑制EGFR基因表达的siRNA及其前体和应用
JP6931733B2 (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
CN107921147B (zh) 一种新的前体miRNA及其在肿瘤治疗中的应用
Zhao et al. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9
CN109563513A (zh) 一种抑制K-RAS基因表达的siRNA及其前体和应用
US20230056466A1 (en) Novel precursor mirna and application thereof in tumor treatment
CN109971756A (zh) 抑制EGFR表达的siRNA及其前体和应用
CN107075515A (zh) C/EBPα组合物和使用方法
CN107375944A (zh) 一种靶向抗恶性黑色素瘤的达卡巴嗪和miR‑205共载外泌体及其制备方法和应用
US9284557B2 (en) Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of cancer
CN113616645A (zh) 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用
CN115607674B (zh) Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
US10835551B2 (en) Double-stranded nucleic acid molecule, DNA, vector, cancer cell growth inhibitor, cancer cell migration inhibitor, and drug
CN101787368B (zh) 抑制人Z38基因表达的siRNA及其在制备抗乳腺肿瘤药物中的应用
CN104840976A (zh) MiR125及其调控的原癌基因Pokemon表达的用途
JP5976922B2 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
CN116539884A (zh) 氧甾醇结合蛋白osbpl2作为结直肠癌分子标志物及其治疗靶点的应用
TW202011956A (zh) 含４－乙醯基－安卓奎諾－ｂ之組合物用於製備抑制腦癌細胞或腦癌幹細胞生長之藥物的用途
CN117025603A (zh) 抑制信号转导及转录激活蛋白3基因表达的siRNA、纳米粒子及其用途
CN117771208A (zh) 一种双重抑制肿瘤的纳米粒子及其制备方法和应用
CN114958839A (zh) 抑制肌肉瘤细胞中FOXO1基因表达的siRNA序列及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant